CureVac (NASDAQ:CVAC) was down 6.6% on Friday . The stock traded as low as $95.79 and last traded at $98.80. Approximately 1,860 shares changed hands during trading, a decline of 100% from the average daily volume of 947,213 shares. The stock had previously closed at $105.80.
A number of analysts have weighed in on CVAC shares. Zacks Investment Research cut CureVac from a “buy” rating to a “hold” rating in a research report on Friday, April 23rd. Credit Suisse Group assumed coverage on CureVac in a research report on Monday, April 26th. They set an “underperform” rating for the company. Finally, Guggenheim assumed coverage on shares of CureVac in a research note on Monday, May 3rd. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $75.25.
The stock has a market cap of $18.40 billion and a price-to-earnings ratio of -87.88. The company has a quick ratio of 5.55, a current ratio of 5.61 and a debt-to-equity ratio of 0.04. The firm’s 50-day moving average is $108.01.
CureVac Company Profile (NASDAQ:CVAC)
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza.
Further Reading: Why is the price-sales ratio important?
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.